New treatment strategy for children with newly diagnosed liver cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 3 study tests a modified treatment plan for children newly diagnosed with hepatoblastoma, a type of liver cancer. It may help improve how well treatment works and how safely it can be given by using a structured approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be diagnosed with newly found hepatoblastoma confirmed by a tissue biopsy (unless biopsy is unsafe in an emergency)
- Be a child patient (typical for pediatric trials) who can do normal activities or limited activity (ECOG 0–2, or age-based activity score)
- Have enough kidney and liver function for chemotherapy (specific lab cutoffs for creatinine clearance/GFR and bilirubin/AST/ALT)
- Not have had chemotherapy or liver-targeted cancer treatments before, except surgery to remove the tumor
- Not have certain blockers: no other investigational drugs, no other cancer medicines, no uncontrolled infection, and no prior solid organ transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to see if chemotherapy will work for children with hepatoblastoma, a type of liver cancer. It uses a blood test (ctDNA 5hmc) to help predict treatment success and monitor if the cancer comes back.
This Phase 1/2 trial tests an immune-cell treatment (ET140203 T cells) in children and teens with certain liver cancers that have come back or did not respond to standard treatment. It aims to see whether these T cells can shrink tumors and is mainly focused on safety and early effectiveness.
This trial tests a combination of an immunotherapy (pucotenlimab), a targeted therapy (lenvatinib), and chemotherapy for children with advanced or relapsed hepatoblastoma that hasn't responded to prior treatment. The goal is to see if this combination can help shrink or control the tumor.
This Phase 2 trial tests how doctors choose treatment for infants and young children with newly diagnosed medulloblastoma, based on MRI/CSF staging and lab testing of the tumor. It may help by matching therapy intensity to the child’s specific risk level and tumor type.
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
Hear when a new Hepatoblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.